Novo Nordisk: FDA may add warnings to liraglutide's label

08/19/2008 | Bloomberg · Reuters

Novo Nordisk said the FDA may call for stronger warnings on liraglutide, an experimental diabetes medicine, after two patients who took Byetta -- a similar drug from Amylin Pharmaceuticals and Eli Lilly and Co. -- died because of inflamed pancreases. The agency is working to revise the label for Byetta, which belongs to a class of drugs called incretin mimetics. Novo Nordisk said it found no proof of a "statistically significant" increase in cases of pancreatitis in clinical-trial patients treated with liraglutide.

View Full Article in:

Bloomberg · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI